MannKind Expects FDA to Approve Inhaled Insulin, Edstrom Says

MannKind Corp.’s President and Chief Operating Officer Hakan Edstrom said he expects U.S. regulators to approve the company’s experimental inhaled insulin drug by Jan. 16, challenging analysts who predicted a delay.
BusinessWeek